The standard diagnostic investigation of chronic diarrhoea usually includes a variety of laboratory investigations, such as complete blood count, serum biochemistry panel, urinalysis, faecal exams, evaluation of pancreatic function and inflammation, endocrine assays (*i.e*. adrenal gland function), as well as diagnostic imaging procedures (*e.g*. abdominal radiographs/ultrasound) and GI endoscopy, including mucosal biopsies for histopathological examination. Empirical treatment is often trialled and can include dietary interventions, parasiticides and antibacterials (ABs) such as metronidazole or tylosin (Jergens *et al*. [2003](#jsap13122-bib-0016){ref-type="ref"}, Kilpinen *et al*. [2015](#jsap13122-bib-0019){ref-type="ref"}, Allenspach *et al*. [2016](#jsap13122-bib-0002){ref-type="ref"}). These empirical treatments are often administered before GI endoscopy/mucosal biopsy because they may represent effective strategies for managing canine chronic enteropathy (Volkmann *et al*. [2017](#jsap13122-bib-0035){ref-type="ref"}, Heilmann *et al*. [2018](#jsap13122-bib-0014){ref-type="ref"}). Corticosteroids and other immunosuppressants are needed in some cases to control clinical signs, but are generally recommended after other treatment strategies have been exhausted and after mucosal biopsies have been obtained, which are necessary to diagnose intestinal inflammation and other GI disorders such as (primary) lymphangiectasia, infectious agents (*e.g*. fungal infections, adherent‐invasive *Escherichia coli*) and neoplastic infiltration (*e.g*. lymphoma).

Antibiotic‐responsive diarrhoea is recognised as one form of chronic enteropathy. Its clinical presentation is indistinguishable from other types of chronic enteropathy; it is associated with intestinal microbiota dysbiosis (Hall [2011](#jsap13122-bib-0013){ref-type="ref"}) and responds exquisitely well to administration of ABs, while it often recurs as soon as they are withdrawn (Hall [2011](#jsap13122-bib-0013){ref-type="ref"}, Westermarck [2016](#jsap13122-bib-0039){ref-type="ref"}). Most often, tylosin (tylosin‐responsive diarrhoea) (Westermarck *et al*. [2005](#jsap13122-bib-0040){ref-type="ref"}), metronidazole (Allenspach *et al*. [2016](#jsap13122-bib-0002){ref-type="ref"}) and oxytetracycline (Hall [2011](#jsap13122-bib-0013){ref-type="ref"}) have been used as therapy. Diagnosis is based on a positive response to ABs after exclusion of other conditions as outlined above. In antibiotic‐responsive diarrhoea, histopathology of intestinal biopsies, if acquired, frequently shows no or only mild non‐specific inflammatory infiltrates or abnormalities (Hall [2011](#jsap13122-bib-0013){ref-type="ref"}, Volkmann *et al*. [2017](#jsap13122-bib-0035){ref-type="ref"}). However, although ABs constitute an empirical therapy instituted by many clinicians in dogs with chronic diarrhoea, this might lead to unnecessary administration or overuse of ABs, as not all of these dogs will eventually be diagnosed with antibiotic‐responsive diarrhoea. This practice is of even greater concern considering recent reports in which antibiotic‐responsive diarrhoea was retrospectively reported in only 11 of 136 (8%) (Volkmann *et al*. [2017](#jsap13122-bib-0035){ref-type="ref"}) and 33 of 203 (16.2%) (Allenspach *et al*. [2016](#jsap13122-bib-0002){ref-type="ref"}) of dogs with chronic diarrhoea, respectively. In addition, a study by Jergens *et al*. ([2010](#jsap13122-bib-0018){ref-type="ref"}) is noteworthy, because it shows oral prednisone alone to be clinically as effective as prednisone *plus* metronidazole in dogs suffering from inflammatory bowel disease, suggesting that the use of antibiotics might not always be necessary.

Based on our experience and on the evidence in the literature reported here, the aim of this report is to make a strong argument against the empirical use of ABs when routinely managing dogs with suspected chronic enteropathy. The use of ABs should be reserved for patients in which all other conditions are excluded and other empirical treatments have been exhausted. The following paragraphs will elucidate potential detrimental effects of ABs on individual gut health and public health.

EFFECTS OF ANTIBACTERIALS ON GI MICROBIOTA {#jsap13122-sec-0002}
==========================================

Although the effect of AB administration on the faecal microbiota still needs to be defined further, some aspects have been investigated in humans (Rizzatti *et al*. [2018](#jsap13122-bib-0028){ref-type="ref"}) and both healthy and diseased animals. It is known that AB administration causes changes in the composition and richness of the intestinal microbiota in dogs and cats and that this dysbiosis can be detrimental to overall host health (Suchodolski [2016](#jsap13122-bib-0033){ref-type="ref"}), similarly to those presenting with inflammatory bowel disease (Minamoto *et al*. [2015](#jsap13122-bib-0022){ref-type="ref"}). Specifically, the administration of oral tylosin (20 to 22 mg/kg SID for 14 days) to healthy dogs was associated with changes in the proportions of jejunal bacteria (*e.g*. increases in *Enterococcus*‐like organisms and *Pasteurella* spp.). Microbiota alterations (*i.e*. increase of *Escherichia coli*‐like organisms) were still observed 14 days after withdrawal of tylosin (Suchodolski *et al*. [2009](#jsap13122-bib-0034){ref-type="ref"}). The phylogenetic composition of the microbiota following tylosin withdrawal was comparable to day 0 in only two of five dogs, while bacterial diversity was similar in three of five dogs, suggesting a possible long‐term adverse effect in some animals (Suchodolski *et al*. [2009](#jsap13122-bib-0034){ref-type="ref"}). Very recently, as found in healthy dogs, it was shown that the administration of tylosin (20 mg/kg PO BID) induced dysbiosis‐ and eubiosis was not restored by 56 days following tylosin discontinuation, leading the authors to conclude that in these patients *"... reestablishment of the native microbiota is possible but not guaranteed*." (Manchester *et al*. [2019](#jsap13122-bib-0020){ref-type="ref"}). Faecal bacterial diversity was also reduced when administering oral metronidazole for 14 days (12.5 mg/kg BID) to healthy dogs (Igarashi *et al*. [2014](#jsap13122-bib-0015){ref-type="ref"}). Similarly, oral administration of amoxicillin (10 mg/kg BID for 7 days) to healthy dogs resulted in differences in faecal bacterial composition before and after administration, with many faecal *E. coli* isolates showing increased resistance to multiple ABs during and after treatment (Grønvold *et al*. [2010](#jsap13122-bib-0012){ref-type="ref"}). Interestingly, in dogs with tylosin‐responsive diarrhoea, there were increases in faecal *Enterococcus* spp. and other potentially probiotic bacteria (including lactic acid bacteria) (Kilpinen *et al*. [2015](#jsap13122-bib-0019){ref-type="ref"}). It was speculated that there could be a possible indirect probiotic effect of tylosin by exerting a selection pressure, resulting in a relative increase in tylosin‐resistant enterococci (Kilpinen *et al*. [2015](#jsap13122-bib-0019){ref-type="ref"}). Although these results are interesting, there are still concerns that antibacterial resistance could be passed horizontally from commensal bacteria or alleged probiotics to pathogenic bacteria sharing the same intestinal environment (von Wintersdorff *et al*. [2016](#jsap13122-bib-0036){ref-type="ref"}).

Furthermore, the metabolic pathways through which ABs may alter gut homeostasis are still under investigation. For example, a recent paper suggests that the administration of a cocktail of antibiotics in mice (antibiotic‐induced microbiome depletion) in addition to modifying the abundance of some bacterial species, also altered glucose homeostasis and luminal short‐chain fatty acid concentration (enterocytes use glucose instead of butyrate, which is reduced in the intestinal lumen) and bile acid metabolism (Zarrinpar *et al*. [2018](#jsap13122-bib-0043){ref-type="ref"}).

Additionally, it is anecdotally reported that select antimicrobials may have immunomodulatory or anti‐inflammatory actions in treating chronic enteropathy; in particular, metronidazole has recognised immunosuppressive and anti‐inflammatory properties (Shakir *et al*. [2011](#jsap13122-bib-0032){ref-type="ref"}). In one small pilot study, the effects of metronidazole, tylosin and conjugated linoleic acid on immune function were evaluated in healthy dogs (Jergens *et al*. [2007](#jsap13122-bib-0017){ref-type="ref"}). In this study, peripheral blood mononuclear cells were isolated, incubated with graded doses of the antibiotics and conjugated linoleic acid, and immune responses were investigated using MTT cytotoxicity assay, immunostaining and flow cytometry of B and T lymphocyte subpopulations and in vitro mitogen‐induced lymphocyte proliferation (^3^H‐thymidine incorporation). Results indicated that metronidazole and tylosin, at different dosages, were not successful in arresting mitogen‐stimulated proliferation of lymphocytes; in contrast, conjugated linoleic acid was shown to directly inhibit peripheral blood mononuclear cell blastogenesis. Moreover, it must also be remembered that the use of antimicrobials for non‐antimicrobial effects is questionable and discouraged (Weese *et al*. [2015](#jsap13122-bib-0038){ref-type="ref"}).

ANTIBACTERIAL RESISTANCE {#jsap13122-sec-0003}
========================

Antibiotic resistance represents one of the most serious and imminent health‐related problems worldwide (WHO [2017](#jsap13122-bib-0042){ref-type="ref"}); the last joint EFSA/ECDC report Antimicrobial resistance in Europe, (<http://www.efsa.europa.eu/it/interactive_pages/AMR_Report_2016>) based on 2016 data reflects on this alarming situation. The problem is also recognised in companion animals (Peter *et al*. [2017](#jsap13122-bib-0026){ref-type="ref"}), with serious potential concerns for human health associated with methicillin‐resistant *Staphylococcus aureus* (MRSA) (Rossi *et al*. [2017](#jsap13122-bib-0030){ref-type="ref"}). More specifically, for complaints related to the digestive tract, the gut microbiota has been considered as a dynamic reservoir of antibiotic resistance, termed the ("gut resistome"), which can be affected by the administration of ABs (Rizzatti *et al*. [2018](#jsap13122-bib-0028){ref-type="ref"}). A recent report showed that 54% of isolates of *Clostridium perfringens* from dogs with acute diarrhoea, which had not been treated with antibiotics, presented with a decreased susceptibility to metronidazole (Gobeli *et al*. [2012](#jsap13122-bib-0011){ref-type="ref"}). Moreover, dogs are also considered a possible reservoir of antibiotic resistant strains potentially dangerous for human patients. This includes the discovery of epidemic ribotypes of multiresistant *Clostridioides (Clostridium) difficile* (Nagy [2018](#jsap13122-bib-0023){ref-type="ref"}) in dogs with GI disorders (Orden *et al*. [2017](#jsap13122-bib-0024){ref-type="ref"}).

ALTERNATIVE INTESTINAL MICROBIOTA MODULATION {#jsap13122-sec-0004}
============================================

There is growing interest and clinical evidence supporting alternative treatments to modulate bacterial populations, which could include the administration of prebiotics, probiotics or synbiotics. Several studies show that probiotics are likely beneficial in cases of diarrhoea, even in dogs suffering from inflammatory bowel disease (Rossi *et al*. [2014](#jsap13122-bib-0029){ref-type="ref"}, White *et al*. [2017](#jsap13122-bib-0041){ref-type="ref"}, Rossi *et al*. [2018](#jsap13122-bib-0031){ref-type="ref"}). Another promising modality is faecal microbiota transplantation. It has been recommended for recurrent *Clostridioides (Clostridium) difficile* infections in humans, a hospital‐acquired infection that usually develops after extensive AB treatment (Cammarota *et al*. [2015](#jsap13122-bib-0005){ref-type="ref"},Cammarota *et al*. [2017](#jsap13122-bib-0006){ref-type="ref"}, Quraishi *et al*. [2017](#jsap13122-bib-0027){ref-type="ref"}). Even though an equivalent of this condition is lacking in dogs (it is not comparable to an infection with *Clostridioides \[Clostridium\] difficile* sometimes seen in dogs with both acute and chronic diarrhoea) (Marks *et al*. [2011](#jsap13122-bib-0021){ref-type="ref"}), it is reasonable to assume that dysbiosis caused by inappropriate AB treatment should be avoided in canine patients. Results from faecal microbiota transplantation in human subjects suggest that the attempt to "restore" a physiological microbiota could be more effective than ABs alone in some specific cases (Cammarota *et al*. [2017](#jsap13122-bib-0006){ref-type="ref"}, Quraishi *et al*. [2017](#jsap13122-bib-0027){ref-type="ref"}). Unfortunately, large scale studies on the clinical effect (short‐ and long‐term effects) or the efficacy of restoring eubiosis by administration of faecal microbiota transplantation are currently lacking. The optimal donor screening and indication, as well as the best modality and frequency of administration of faecal microbiota transplantation in dogs, is currently unknown, because only a few studies are available (Chaitman *et al*. [2016](#jsap13122-bib-0009){ref-type="ref"}, Burton et al. 2016, Pereira et al. 2018). We are still a far way away from suggesting its use as a routine treatment in dogs with acute and/or chronic diarrhoea, because scientific evidence from appropriately designed prospective studies is lacking. However, these data underline that ABs may not be the best option to treat some forms of infectious diarrhoea; on the contrary, alternative attempts to modulate and restore intestinal microbiota should be considered in diarrhoeic dogs.

PROPOSAL FOR RATIONAL USE OF ANTIBACTERIALS IN THE DIAGNOSIS AND TREATMENT OF CHRONIC DIARRHOEA IN DOGS {#jsap13122-sec-0005}
=======================================================================================================

The necessity of avoiding empirical and injudicious use of antibacterials in diarrhoeic dogs has previously been emphasised (Marks *et al*. [2011](#jsap13122-bib-0021){ref-type="ref"}, Heilmann *et al*. [2018](#jsap13122-bib-0014){ref-type="ref"}). Furthermore, considering the global concern for rising antibiotic resistance, the dysbiosis associated with indiscriminate use of ABs, and the potentially associated worsening of GI signs, the risks for both the individual patient and potential harm to the general public of using ABs in chronic GI diseases needs to be fully appreciated by clinicians.

Clinicians should consider using ABs only *after* appropriate dietary trials have been unsuccessful and only *after* histopathologic evaluation of GI biopsies in all cases in which it is possible. In cases in which biopsies cannot be acquired we recommend use of ABs only after other empirical therapeutic trials are unsuccessful. In short, after having excluded all conditions (Fig [1](#jsap13122-fig-0001){ref-type="fig"}) that would not benefit from administration of ABs, they can be considered for those canine chronic diarrhoeic patients with signs of true primary infection that justify AB usage or in those patients in which endoscopy is not possible (or histopathology is not conclusive) and that are not responsive to any other treatment. They may be an option in those cases showing signs of systemic inflammatory response syndrome (*e*.*g*. pyrexia, inflammatory left‐shifted leucogram or leucopenia) or in cases of acute infection with a known enteric bacterial pathogen that is not self‐limiting or responding to symptomatic treatment. However, considering that there are few indications for using ABs in chronic diarrhoea, because primary bacterial agents causing non‐self‐limiting disease are rare (Marks *et al*. [2011](#jsap13122-bib-0021){ref-type="ref"}), it means that these treatments should be reserved for specific diseases and in accordance with appropriate AB resistance testing panels, avoiding the empirical use of broad spectrum ABs such as amoxicillin/clavulanic acid or fluoroquinolones.

![Diagnostic algorithm for the diarrhoeic dog. This algorithm is suggested by our combined clinical experience, but different parts are also variably widely reported in literature, including (but not limited to): Jergens *et al*. [2003](#jsap13122-bib-0016){ref-type="ref"}, Allenspach *et al*. [2007](#jsap13122-bib-0001){ref-type="ref"}, Cerquetella *et al*. [2010](#jsap13122-bib-0007){ref-type="ref"}, Washabau *et al*. [2010](#jsap13122-bib-0037){ref-type="ref"}, Allenspach *et al*. [2016](#jsap13122-bib-0002){ref-type="ref"}, Westermarck et al. Westermarck [2016](#jsap13122-bib-0039){ref-type="ref"}, Erdmann & Heilmann [2017](#jsap13122-bib-0010){ref-type="ref"}, Volkmann *et al*. [2017](#jsap13122-bib-0035){ref-type="ref"}, Cerquetella *et al*. [2018](#jsap13122-bib-0008){ref-type="ref"}, Heilmann *et al*. [2018](#jsap13122-bib-0014){ref-type="ref"}. It is recommended to use (targeted, not broad spectrum) ABs in the chronic diarrhoeic dog (when there is no clinical evidence of a medical rationale for their immediate use), only at the end of the diagnostic protocol, once GI biopsies are performed, and with evidence of infectious causes. \*In some cases more than one diet change may be needed, and for this reason duration of diet trial may vary. ^§^Depending on the severity of clinical condition, these trials can be postponed going forward with the algorithm. FRD Food‐responsive diarrhoea, IBD Inflammatory bowel disease, SRD Immunosuppressive/steroid‐responsive diarrhoea](JSAP-61-211-g001){#jsap13122-fig-0001}
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